Physician profile
Prashant Pendyala
NPI 1801842844
$101,224.06
in general payments reported to CMS, 2019-2025
12 companies · $4,825 in 2025
The $4,825 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.79 · 2020: $31.34 · 2021: $218 · 2022: $26K · 2023: $41K · 2024: $29K · 2025: $4,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Consulting Fee: $4,225 · Food and Beverage: $2,723 · Travel and Lodging: $1,774 · Education: $69.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,948.00 |
| Consulting Fee | $4,225.00 |
| Food and Beverage | $2,723.30 |
| Travel and Lodging | $1,773.74 |
| Education | $69.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $39,491.22 | 2022-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $25,754.85 | 2022-2023 | |
| Lilly USA, LLC | $18,676.77 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,105.44 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $6,052.75 | 2020-2023 | Benlysta |
| Travere Therapeutics, INC. | $856.11 | 2023-2025 | Filspari |
| Amgen INC. | $139.08 | 2025 | Otezla, Repatha, Tavneos |
| Philips North America LLC | $74.32 | 2021 | |
| Fresenius USA Marketing, INC. | $26.43 | 2019-2020 | |
| Horizon Therapeutics Plc | $19.73 | 2023 | Krystexxa |
| Shield Therapeutics INC | $13.76 | 2024 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Pendyala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.